NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/15/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization14,162 mln
Float175 mln
Earnings Date10/29/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-1.49
Manipulation likely
1-Year Forecast
109
Exceptional upside
Relative Strength
14
/ 100
Significantly lagging
Pre-Tax Margin
-99%
Severely loss-making
Altman Z-Score
-2.91
Deeply distressed
Business Description
BridgeBio Pharma is a drug development company focused on finding and delivering treatments for patients with inherited genetic conditions. Founded in 2015 and based in Palo Alto, California, the company has several medicines either already on the market or in late-stage clinical testing, targeting conditions that affect the heart, bones, muscles, and other systems. BridgeBio works alongside partners including Bayer, Alexion, Novartis, and Stanford University to advance its pipeline of therapies.
